RxDoctor Payments Data

Hope Owens

Family · Quincy, ILNPI 1194142950

Payments from drug & device makers

$8,735in general payments, 2019–2025

Across 499 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$903
  • Merck$737
  • Boston Scientific$662
  • Amgen$656
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$8,709100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,735 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$207,594
Medicare patients
1,042
Services billed
2,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban520$417,830
XareltoRivaroxaban245$266,710
EntrestoSacubitril/Valsartan75$100,104
MultaqDronedarone Hcl50$91,609
Repatha SureclickEvolocumab39$31,049
JardianceEmpagliflozin21$23,756
BrilintaTicagrelor22$17,721
Repatha SyringeEvolocumab17$14,849
Praluent PenAlirocumab25$12,509
Ranolazine ErRanolazine109$9,126
Metoprolol Succinate655$6,151
Amiodarone Hcl295$3,927
Atorvastatin Calcium541$3,670
Losartan Potassium426$3,237
Isosorbide Mononitrate ErIsosorbide Mononitrate411$2,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$479$417,830520 claims
Johnson & JohnsonXarelto$1,422$266,710245 claims
NovartisEntresto$1,028$100,10475 claims
Sanofi-aventis U.S. LLCMultaq$238$91,60950 claims
Boehringer IngelheimJardiance$314$23,75621 claims
AstraZenecaBrilinta$329$17,72122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Quincy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →